Purple Biotech (PPBT) ehemals KTOV (Mkap $16 M) ( Cash $17 M) US Zulassungsantrag diesen Quartal (Seite 151)
eröffnet am 18.07.17 17:14:19 von
neuester Beitrag 31.03.24 12:32:14 von
neuester Beitrag 31.03.24 12:32:14 von
Beiträge: 1.796
ID: 1.257.452
ID: 1.257.452
Aufrufe heute: 0
Gesamt: 149.337
Gesamt: 149.337
Aktive User: 0
ISIN: US74638P1093 · WKN: A2QLTP · Symbol: PPBT
0,7450
USD
-6,88 %
-0,0550 USD
Letzter Kurs 25.05.24 Nasdaq
Neuigkeiten
| TitelBeiträge |
|---|
21.05.24 · globenewswire  |
25.04.24 · globenewswire |
28.03.24 · globenewswire |
14.03.24 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,6220 | +108,03 | |
| 2,1100 | +64,33 | |
| 55,50 | +36,03 | |
| 1,7870 | +28,56 | |
| 1,0500 | +23,53 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,7000 | -31,17 | |
| 2,6200 | -43,04 | |
| 0,7900 | -45,89 | |
| 1,0200 | -53,64 | |
| 4,1200 | -66,17 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 64.149.685 von BTRRR am 23.06.20 20:31:23Genug um mir hier schnell ein Urteil zu bilden, du hast aber auch gute Werte im Depot, das hatte ich dir schon in deinem Forum geschrieben, also bitte nicht gleich beleidigt sein. 
Antwort auf Beitrag Nr.: 64.149.016 von BTRRR am 23.06.20 19:44:29Wann soll denn eine "Verkündung neuer Partner" bekanntgegeben werden??? Momentan ist das Ding ja total abgeschmiert... was für 'n Sch....
Antwort auf Beitrag Nr.: 64.149.685 von BTRRR am 23.06.20 20:31:23Einfach schwimmen, einfach schwimmen.....vielleicht solltest du Wirecard kaufen, die sind aktuell stark am schwimmen
Antwort auf Beitrag Nr.: 64.149.658 von fisch29 am 23.06.20 20:29:49Da hat sich aber jemand intensiv mit KTOV beschäftigt😅😂
typische pump and dump aktie halt, was hattest du erwartet?
Trading Spotlight
Antwort auf Beitrag Nr.: 64.148.878 von Liongold am 23.06.20 19:32:46Unglaublich, ist man 1h nicht da und dann sowas😂😡 tja, mit dem war also sicher nicht zu rechnen! Es ändert aber an der Tatsache nicht, dass 2$ mit einem guten Partner möglich werden!
Antwort auf Beitrag Nr.: 64.148.878 von Liongold am 23.06.20 19:32:46http://www.globenewswire.com/news-release/2020/06/23/2052250…
auch gerade gelesen... mist
auch gerade gelesen... mist
bin wieder drin 78 cent
35 Mil $ public offering zu 0,90 $ 😂😂😂 ... Die Typen sind wirklich skrupellos .... Firma ist bis Q2 2021 durchfinanziert ... und bei der ersten positiven Woche seit Monaten hauen sie gleich wieder ein offering rein.
TEL-AVIV, Israel, June 23, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that it has entered into definitive agreements with several healthcare-focused institutional investors for the purchase and sale of 38,888,892 of the Company’s ordinary shares represented by American Depositary Shares (ADSs) and warrants to purchase up to an aggregate of 19,444,446 ADSs, at a combined purchase price of $0.90 per ADS and associated warrant, in a registered direct offering, for aggregate gross proceeds of approximately $35.0 million. Each ADS represents one ordinary share, no par value, of Kitov. The offering is expected to close on or about June 25, 2020, subject to satisfaction of customary closing conditions.
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
The warrants will have an exercise price of $0.90 per ADS and will be exercisable at any time upon issuance and will expire five years from the date of issuance.
Kitov intends to use the net proceeds of this offering to fund the development of its oncology drug candidates, acquisition of new assets and for general working capital purposes.
The securities described above are being offered by Kitov pursuant to a “shelf” registration statement on Form F-3 (File No. 333- 235327) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) on December 2, 2019 and declared effective by the SEC on December 13, 2019. The offering of such securities will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and accompanying prospectus relating to the securities being offered will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC's website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (646) 975-6996 or e-mail at placements@hcwco.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
https://finance.yahoo.com/news/kitov-announces-35-0-million-…
TEL-AVIV, Israel, June 23, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that it has entered into definitive agreements with several healthcare-focused institutional investors for the purchase and sale of 38,888,892 of the Company’s ordinary shares represented by American Depositary Shares (ADSs) and warrants to purchase up to an aggregate of 19,444,446 ADSs, at a combined purchase price of $0.90 per ADS and associated warrant, in a registered direct offering, for aggregate gross proceeds of approximately $35.0 million. Each ADS represents one ordinary share, no par value, of Kitov. The offering is expected to close on or about June 25, 2020, subject to satisfaction of customary closing conditions.
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
The warrants will have an exercise price of $0.90 per ADS and will be exercisable at any time upon issuance and will expire five years from the date of issuance.
Kitov intends to use the net proceeds of this offering to fund the development of its oncology drug candidates, acquisition of new assets and for general working capital purposes.
The securities described above are being offered by Kitov pursuant to a “shelf” registration statement on Form F-3 (File No. 333- 235327) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) on December 2, 2019 and declared effective by the SEC on December 13, 2019. The offering of such securities will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and accompanying prospectus relating to the securities being offered will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC's website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (646) 975-6996 or e-mail at placements@hcwco.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
https://finance.yahoo.com/news/kitov-announces-35-0-million-…
Antwort auf Beitrag Nr.: 64.146.181 von BTRRR am 23.06.20 16:48:03Alles nur Abverkäufe.Warum geht die auf einmal so rapide abwärts.
Durchsuchen
